Journal
CANCER BIOLOGY & THERAPY
Volume 10, Issue 9, Pages 843-857Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/cbt.10.9.13738
Keywords
chemotherapy; resistance; targeted therapy; RNAi screen; integrative biology; DNA damage; synthetic lethality
Categories
Funding
- Genentech
- NIH [CA153077, CA120091, CA63366, CA113342, CA-06927]
- Fox Chase Cancer Center Head and Neck Cancer Keystone
- Pew Charitable Trust
Ask authors/readers for more resources
In recent years, oncologists have begun to conclude that chemotherapy has reached a plateau of efficacy as a primary treatment modality, even if toxicity can be effectively controlled. Emerging specific inhibitors of signaling and metabolic pathways (i.e., targeted agents) contrast with traditional chemotherapy drugs in that the latter primarily interfere with the DNA biosynthesis and the cell replication machinery. In an attempt to improve on the efficacy, combination of targeted drugs with conventional chemotherapeutics has become a routine way of testing multiple new agents in early phase clinical trials. This review discusses the recent advances including integrative systematic biology and RNAi approaches to counteract the chemotherapy resistance and to buttress the selectivity, efficacy and personalization of anticancer drug therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available